TipRanks
NeonMind Biosciences Inc (DE:6UF0)
FRANKFURT:6UF0
Germany Market
6UF0
NeonMind Biosciences Inc
RESEARCH TOOLSreports

NeonMind Biosciences Inc (6UF0) Ratios

1 Followers

NeonMind Biosciences Inc Ratios

DE:6UF0's free cash flow for Q1 2026 was C$0.00. For the 2026 fiscal year, DE:6UF0's free cash flow was decreased by C$ and operating cash flow was C$0.00. See a summary of the company’s cash flow.
Ratios
TTM
Jun 25Jun 24Mar 24Feb 23
Liquidity Ratios
Current Ratio
 ― 0.40 0.03 0.21 0.19
Quick Ratio
 ― 0.40 0.03 0.16 0.19
Cash Ratio
 ― 0.25 <0.01 0.04 0.05
Solvency Ratio
 ― -1.00 -0.77 >-0.01 -1.33
Operating Cash Flow Ratio
 ― -1.45 -0.04 -0.85 -1.58
Short-Term Operating Cash Flow Coverage
 ― -13.60 -0.08 -1.09 0.00
Net Current Asset Value
C$ ―C$ -1.47MC$ -1.95MC$ -1.05MC$ -1.40M
Leverage Ratios
Debt-to-Assets Ratio
 ― 1.04 13.10 1.44 6.54
Debt-to-Equity Ratio
 ― -1.79 -0.63 -1.69 -0.60
Debt-to-Capital Ratio
 ― 2.27 -1.68 2.44 -1.53
Long-Term Debt-to-Capital Ratio
 ― 2.49 -1.68 2.44 -1.53
Financial Leverage Ratio
 ― -1.72 -0.05 -1.17 -0.09
Debt Service Coverage Ratio
 ― -6.14 >-0.01 >-0.01 -7.26
Interest Coverage Ratio
 ― -7.24 -6.81 0.00 -6.27
Debt to Market Cap
 ― 0.19 2.74K 1.02 3.65
Interest Debt Per Share
 ― 0.01 24.24 0.02 1.00
Net Debt to EBITDA
 ― -0.61 -1.33K -10.00T> -0.46
Profitability Margins
Gross Profit Margin
―0.00%0.00%0.00%0.00%
EBIT Margin
―0.00%0.00%0.00%0.00%
EBITDA Margin
―0.00%0.00%0.00%0.00%
Operating Profit Margin
―0.00%0.00%0.00%0.00%
Pretax Profit Margin
―0.00%0.00%0.00%0.00%
Net Profit Margin
―0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin
―0.00%0.00%0.00%0.00%
Net Income Per EBT
―99.61%99.11%100.00%100.00%
EBT Per EBIT
―132.15%145.56%212.70%116.16%
Return on Assets (ROA)
―-160.50%-1684.68%-0.50%-1571.78%
Return on Equity (ROE)
―275.95%80.67%0.59%145.10%
Return on Capital Employed (ROCE)
―-324.73%55.82%0.28%315.53%
Return on Invested Capital (ROIC)
―-275.84%130.96%-0.40%566.92%
Return on Tangible Assets
―-160.50%-1684.68%-0.50%-1571.78%
Earnings Yield
―-29.35%-183757.38%-0.18%-876.96%
Efficiency Ratios
Receivables Turnover
 ― 0.00 0.00 0.00 0.00
Payables Turnover
 ― 0.00 0.00 0.00 0.00
Inventory Turnover
 ― 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 ― 0.00 0.00 0.00 0.00
Asset Turnover
 ― 0.00 0.00 0.00 0.00
Working Capital Turnover Ratio
 ― 0.00 0.00 0.00 0.00
Cash Conversion Cycle
 ― 0.00 0.00 0.00 0.00
Days of Sales Outstanding
 ― 0.00 0.00 0.00 0.00
Days of Inventory Outstanding
 ― 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 ― 0.00 0.00 0.00 0.00
Operating Cycle
 ― 0.00 0.00 0.00 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 ― >-0.01 -1.61 -0.03 -0.96
Free Cash Flow Per Share
 ― >-0.01 -1.61 -0.03 -1.08
CapEx Per Share
 ― <0.01 0.06 <0.01 0.12
Free Cash Flow to Operating Cash Flow
 ― 1.00 1.00 1.15 1.13
Dividend Paid and CapEx Coverage Ratio
 ― -247.16K -26.79 -6.49 -7.89
Capital Expenditure Coverage Ratio
 ― -247.16K -26.79 -6.49 -7.89
Operating Cash Flow Coverage Ratio
 ― -0.87 -0.08 -1.09 -1.28
Operating Cash Flow to Sales Ratio
 ― 0.00 0.00 0.00 0.00
Free Cash Flow Yield
―-16.56%-10748.21%-64.37%-524.99%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― -2.35 -0.54 -562.10 -0.11
Price-to-Sales (P/S) Ratio
 ― 0.00 0.00 0.00 0.00
Price-to-Book (P/B) Ratio
 ― -9.40 >-0.01 -3.31 -0.17
Price-to-Free Cash Flow (P/FCF) Ratio
 ― -6.04 >-0.01 -1.55 -0.19
Price-to-Operating Cash Flow Ratio
 ― -6.04 >-0.01 -1.79 -0.21
Price-to-Earnings Growth (PEG) Ratio
 ― 0.31 <0.01 5.88 <0.01
Price-to-Fair Value
 ― -9.40 >-0.01 -3.31 -0.17
Enterprise Value Multiple
 ― -4.40 -1.33K -10.00T> -0.60
Enterprise Value
 ― 6.93M 1.19M 3.01M 1.04M
EV to EBITDA
 ― -4.40 -1.33K -10.00T> -0.60
EV to Sales
 ― 0.00 0.00 0.00 0.00
EV to Free Cash Flow
 ― -7.01 -13.30 -2.31 -0.86
EV to Operating Cash Flow
 ― -7.01 -13.30 -2.66 -0.97
Tangible Book Value Per Share
 ― >-0.01 -34.23 -0.01 -1.24
Shareholders’ Equity Per Share
 ― >-0.01 -34.17 -0.01 -1.24
Tax and Other Ratios
Effective Tax Rate
 ― 0.00 0.00 0.00 -0.14
Revenue Per Share
 ― 0.00 0.00 0.00 0.00
Net Income Per Share
 ― -0.02 -27.56 >-0.01 -1.80
Tax Burden
 ― 1.00 0.99 1.00 1.00
Interest Burden
 ― 1.12 1.19K 2.13 1.16
Research & Development to Revenue
 ― 0.00 0.00 0.00 0.00
SG&A to Revenue
 ― 0.00 0.00 0.00 0.00
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 0.57 0.06 0.31 0.53
Currency in CAD